M. Michenzie

1821P Safety and preliminary efficacy of vimseltinib in tenosynovial giant cell tumor (TGCT)

W. Tap, P. Rutkowski, H. Gelderblom, 2021, Annals of Oncology.

Phase 1 study of IMGN853, a folate receptor alpha (FR{alpha})-targeting antibody-drug conjugate (ADC) in patients (Pts) with epithelial ovarian cancer (EOC) and other FRA-positive solid tumors.

A. Oza, M. Birrer, H. Borghaei, 2015 .

Preliminary single agent activity of IMGN853, a folate receptor alpha (FR{alpha})-targeting antibody-drug conjugate (ADC), in platinum-resistant epithelial ovarian cancer (EOC) patients (pts): Phase I trial.

A. Oza, M. Birrer, R. Perez, 2015 .